



Press release

## **SHL's Board appoints special interim committee for the financial statements**

**Tel Aviv / Zurich, 12 May 2017** – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN, OTCPK: SMDCY) ("SHL"), a leading provider and developer of advanced personal telemedicine solutions, announced that the company's newly appointed Board of Directors has appointed a special committee to serve as an interim financial statements committee. The elected members are, by alphabetical order, Prof. Amir Lerman, Mr. Xuewen Wu and Ms. Shenlu Xu, all of which have declared that they have the required capacity of reading and understanding financial statements as required under Israeli law. Due to the fact that no Independent (external) directors were elected at yesterday's AGM, the composition of said committee does not fully comply with applicable Israeli law (which SHL voluntarily took upon itself) pursuant to which, inter alia, the majority of members have to be non-dependent directors, with the Chairman being an external one. However, SHL board deemed it right to appoint said special committee to streamline the process of the preparation of the 2016 financial statements and meet the deadline for approval and publication thereof. Once new external directors are elected, at the special general meeting to be reconvened, to the extent approved by same, SHL board will be able to finalize the composition of the committee.

### **About SHL Telemedicine**

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. The Company operates in Israel, Germany, India and the United States in one business segment, Telemedicine services. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: SMDCY. For more information, please visit our web site at [www.shl-telemedicine.com](http://www.shl-telemedicine.com).

### **For further information please contact:**

Martin Meier-Pfister, IRF Communications, Phone : +41 43 244 81 40, [shl@irfcom.ch](mailto:shl@irfcom.ch)

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.